HotCopper on MSN

Paradigm Biopharma engages Danish firm to expand Phase 3 knee OA trial

Paradigm Biopharma (ASX:PAR) has engaged a Scandinavian entity called Nordic Bioscience Clinical Development to expand the ...
Nasdaq

Paradigm Biopharma Highlights Investment Risks and Cautions

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Paradigm Biopharmaceuticals Ltd.
ksn.com

Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up

MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Australia’s Paradigm Biopharmaceuticals Ltd (ASX:PAR) says analysis of six-month trial data shows injectable pentosan polysulfate sodium (iPPS) ...
BioWorld

Holy grail? Paradigm’s injectable Zilosul shows disease-modifying attributes in osteoarthritis

A six-week treatment regimen of Paradigm Biopharmaceuticals Ltd.’s Zilosul (injectable pentosan polysulfate/iPPS) resulted in improvement of both the symptoms of osteoarthritis and preserved or ...
Seeking Alpha

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

Company Combines Existing NR2F6 and Survivin Gene Silencing Findings with Second Generation Checkpoint Inhibitor Approach SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (RGRX) (OTC ...